Home / Market News / $ABBV
benzinga Corporate Catalyst Impact 85/100 ● negative

AbbVie Lowers FY2026 Adjusted EPS Guidance To $13.76-$13.96/Share, Q3 To $3.73-$3.77/Share, On $216M Acquired R&D And Milestone Expense

Oct 5, 2026, 8:14 PM UTC · Primary ticker $ABBV

AbbVie's lowered EPS guidance for both Q3 and FY2026, driven by significant acquired R&D and milestone expenses, signals a near-term earnings headwind. This will likely pressure ABBV shares and could raise concerns about the company's growth trajectory and capital allocation strategy.

This headline represents a significant corporate catalyst for AbbVie. The downward revision of both short-term (Q3) and long-term (FY2026) adjusted EPS guidance indicates a material impact on the company's profitability outlook. The primary driver, a substantial acquired R&D and milestone expense, suggests strategic investments are being made, but at a cost to immediate earnings. This could lead to a sell-off in ABBV shares as investors re-evaluate the company's valuation based on the new guidance. While the R&D expense could signal future growth opportunities, the immediate financial hit creates uncertainty. Trading implications include potential short-term downside for ABBV and increased scrutiny on future pipeline developments.

$ABBV negative Directly impacted by lowered EPS guidance
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.